Marker Therapeutics, Inc. SEC filings MRKR
Marker Therapeutics, Inc. has 904 filings in SEC EDGAR's recent list, going back to Sep 3, 1999. Its latest annual report, Form ARS, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 4, 2026 | May 1, 2026 |
| DEFA14A | Additional proxy material | Mar 20, 2026 | — |
| ARS | Annual report to shareholders | Mar 20, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Mar 20, 2026 | May 1, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 19, 2026 | Mar 18, 2026 |
| 10-K | Annual report | Mar 18, 2026 | Dec 31, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 10, 2026 | May 1, 2026 |
| 8-K | Current report | Feb 9, 2026 | Feb 9, 2026 |
| 4 | Insider transaction | Nov 19, 2025 | Nov 17, 2025 |
| 4 | Insider transaction | Nov 19, 2025 | Nov 17, 2025 |
| 4 | Insider transaction | Nov 19, 2025 | Nov 17, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Nov 17, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| 8-K |
Current report
Results of operations
|
Nov 14, 2025 | Nov 14, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Nov 5, 2025 | Oct 31, 2025 |
| 4 | Insider transaction | Nov 4, 2025 | Oct 31, 2025 |
| 4 | Insider transaction | Nov 4, 2025 | Oct 31, 2025 |
| 3 | Initial insider ownership | Nov 4, 2025 | Oct 31, 2025 |
| 8-K |
Current report
Other events
|
Oct 6, 2025 | Oct 6, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 26, 2025 | Aug 26, 2025 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 20, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 19, 2025 | — |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Aug 18, 2025 | — |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Auditor change
|
Aug 12, 2025 | Aug 7, 2025 |
| 424B7 | Filing | Aug 5, 2025 | — |
| 8-K |
Current report
Material agreement, Other events
|
Jun 17, 2025 | Jun 16, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2025 | Jun 6, 2025 |
| 8-K |
Current report
Other events
|
May 20, 2025 | May 20, 2025 |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2025 | — |
| ARS | Annual report to shareholders | Apr 24, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 6, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2025 | Mar 31, 2025 |
| 10-K | Annual report | Mar 31, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Mar 27, 2025 | Mar 21, 2025 |
| 8-K/A |
Amended current report
Officer or director change, Other events
|
Mar 4, 2025 | Feb 12, 2025 |
| 8-K |
Current report
Officer or director change, Other events
|
Feb 19, 2025 | Feb 12, 2025 |
| 4 | Insider transaction | Feb 14, 2025 | Feb 12, 2025 |
| 4 | Insider transaction | Feb 14, 2025 | Feb 12, 2025 |
| 4 | Insider transaction | Feb 14, 2025 | Feb 12, 2025 |
| 4 | Insider transaction | Feb 14, 2025 | Feb 12, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| DEFA14A | Additional proxy material | Feb 4, 2025 | — |
| DEF 14A | Proxy statement | Feb 4, 2025 | Mar 21, 2025 |
| 8-K |
Current report
Officer or director change
|
Jan 30, 2025 | Jan 24, 2025 |
| EFFECT | Filing | Jan 17, 2025 | — |
| 424B3 | Prospectus | Jan 17, 2025 | — |
| CORRESP | Letter to the SEC | Jan 15, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2025 | — |
| PRE 14A | Preliminary proxy statement | Jan 13, 2025 | Mar 21, 2025 |
| S-3 | Shelf registration | Jan 10, 2025 | — |
| D | Filing | Dec 30, 2024 | — |
| 4 | Insider transaction | Dec 26, 2024 | Dec 23, 2024 |
| 4 | Insider transaction | Dec 23, 2024 | Dec 23, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Dec 23, 2024 | Dec 23, 2024 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Dec 23, 2024 | — |
| 8-K |
Current report
Material agreement, Other events
|
Dec 19, 2024 | Dec 19, 2024 |
| 8-K |
Current report
Other events
|
Dec 17, 2024 | Dec 17, 2024 |
| EFFECT | Filing | Dec 6, 2024 | — |
| 424B3 | Prospectus | Dec 6, 2024 | — |
| CORRESP | Letter to the SEC | Dec 4, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2024 | — |
| S-3 | Shelf registration | Nov 27, 2024 | — |
| 8-K |
Current report
Results of operations
|
Nov 14, 2024 | Nov 14, 2024 |
| 10-Q | Quarterly report | Nov 14, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2024 | Aug 14, 2024 |
| 10-Q | Quarterly report | Aug 14, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Other events
|
Aug 12, 2024 | Aug 12, 2024 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jun 12, 2024 | Jun 6, 2024 |
| SC 13D/A | Amended ownership over 5% (active) | May 17, 2024 | — |
| 8-K |
Current report
Results of operations
|
May 15, 2024 | May 15, 2024 |
| 10-Q | Quarterly report | May 15, 2024 | Mar 31, 2024 |
| ARS | Annual report to shareholders | Apr 26, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 6, 2024 |
| 8-K |
Current report
Other events
|
Apr 8, 2024 | Apr 8, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 26, 2024 | Mar 25, 2024 |
| 10-K | Annual report | Mar 26, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Agreement ended
|
Mar 1, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Material agreement
|
Feb 26, 2024 | Feb 22, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2024 | Jan 8, 2024 |
| 8-K |
Current report
Other events
|
Dec 11, 2023 | Dec 11, 2023 |
| 8-K |
Current report
Officer or director change
|
Nov 20, 2023 | Nov 17, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Other events
|
Sep 11, 2023 | Sep 11, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2023 | Aug 14, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 7, 2023 | Aug 7, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 10, 2023 | Jul 10, 2023 |
| 3 | Initial insider ownership | Jul 5, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Officer or director change
|
Jul 3, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Acquisition or sale of assets
|
Jun 30, 2023 | Jun 26, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 26, 2023 | Jun 26, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 12, 2023 | Jun 12, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2023 | Jun 6, 2023 |
| 4 | Insider transaction | Jun 8, 2023 | Mar 16, 2021 |
| 4 | Insider transaction | Jun 8, 2023 | Jun 6, 2023 |
| 4 | Insider transaction | Jun 8, 2023 | Jun 6, 2023 |
| 4 | Insider transaction | Jun 8, 2023 | Jun 6, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
May 31, 2023 | May 31, 2023 |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| 4 | Insider transaction | May 11, 2023 | May 10, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
May 8, 2023 | May 8, 2023 |
| 8-K |
Current report
Material agreement, Officer or director change, Regulation FD disclosure
|
May 1, 2023 | Apr 27, 2023 |
| ARS | Annual report to shareholders | Apr 28, 2023 | Dec 31, 2022 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 6, 2023 |
| 424B5 | Prospectus supplement | Mar 22, 2023 | — |
| 8-K |
Current report
Results of operations
|
Mar 22, 2023 | Mar 22, 2023 |
| 10-K | Annual report | Mar 22, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Officer or director change
|
Mar 16, 2023 | Mar 13, 2023 |
| SC 13D/A | Amended ownership over 5% (active) | Mar 3, 2023 | — |
| 4 | Insider transaction | Mar 1, 2023 | Feb 27, 2023 |
| 4 | Insider transaction | Mar 1, 2023 | Feb 27, 2023 |
| 4 | Insider transaction | Mar 1, 2023 | Feb 27, 2023 |
| 4 | Insider transaction | Mar 1, 2023 | Feb 27, 2023 |
| 4 | Insider transaction | Mar 1, 2023 | Feb 27, 2023 |
| 4 | Insider transaction | Mar 1, 2023 | Feb 27, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Jan 26, 2023 | Jan 26, 2023 |
| 424B3 | Prospectus | Jan 3, 2023 | — |
| EFFECT | Filing | Dec 30, 2022 | — |
| CORRESP | Letter to the SEC | Dec 29, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 29, 2022 | — |
| S-1 | Registration statement | Dec 23, 2022 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Dec 13, 2022 | Dec 12, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 22, 2022 | Nov 22, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 10-Q | Quarterly report | Nov 10, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Agreement ended
|
Oct 20, 2022 | Oct 16, 2022 |
| 8-K |
Current report
Officer or director change
|
Sep 27, 2022 | Sep 22, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 13, 2022 | Sep 13, 2022 |
| 8-K |
Current report
Listing notice
|
Aug 19, 2022 | Aug 16, 2022 |
| S-8 | Employee stock plan registration | Aug 11, 2022 | — |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 10-Q | Quarterly report | Aug 11, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 4, 2022 | Aug 4, 2022 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 27, 2022 | May 24, 2022 |
| 4 | Insider transaction | May 26, 2022 | May 24, 2022 |
| 4 | Insider transaction | May 26, 2022 | May 24, 2022 |
| 4 | Insider transaction | May 26, 2022 | May 24, 2022 |
| 4 | Insider transaction | May 26, 2022 | May 24, 2022 |
| 4 | Insider transaction | May 26, 2022 | May 24, 2022 |
| 8-K |
Current report
Results of operations
|
May 13, 2022 | May 13, 2022 |
| 10-Q | Quarterly report | May 13, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Apr 26, 2022 | Apr 21, 2022 |
| DEF 14A | Proxy statement | Apr 15, 2022 | May 24, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 6, 2022 | May 24, 2022 |
| 8-K |
Current report
Officer or director change
|
Apr 6, 2022 | Apr 5, 2022 |
| 4 | Insider transaction | Mar 28, 2022 | Mar 24, 2022 |
| 4 | Insider transaction | Mar 28, 2022 | Mar 24, 2022 |
| 4 | Insider transaction | Mar 28, 2022 | Mar 24, 2022 |
| 424B5 | Prospectus supplement | Mar 18, 2022 | — |
| 8-K |
Current report
Results of operations
|
Mar 18, 2022 | Mar 17, 2022 |
| 10-K | Annual report | Mar 17, 2022 | Dec 31, 2021 |
| 4 | Insider transaction | Feb 22, 2022 | Feb 17, 2022 |
| 4 | Insider transaction | Feb 22, 2022 | Feb 17, 2022 |
| 4 | Insider transaction | Feb 22, 2022 | Feb 17, 2022 |
| 4 | Insider transaction | Feb 22, 2022 | Feb 17, 2022 |
| 4 | Insider transaction | Feb 22, 2022 | Feb 17, 2022 |
| 4 | Insider transaction | Feb 22, 2022 | Feb 17, 2022 |
| 4 | Insider transaction | Feb 22, 2022 | Feb 17, 2022 |
| 4 | Insider transaction | Feb 22, 2022 | Feb 17, 2022 |
| 4 | Insider transaction | Feb 22, 2022 | Feb 17, 2022 |
| 8-K |
Current report
Listing notice
|
Feb 18, 2022 | Feb 16, 2022 |
| 8-K |
Current report
Other events
|
Feb 16, 2022 | Feb 16, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 20, 2022 | Jan 19, 2022 |
| 4 | Insider transaction | Dec 9, 2021 | Dec 8, 2021 |
| 3 | Initial insider ownership | Dec 9, 2021 | Dec 8, 2021 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Dec 9, 2021 | Dec 8, 2021 |
| 8-K |
Current report
Officer or director change
|
Nov 15, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 10-Q | Quarterly report | Nov 10, 2021 | Sep 30, 2021 |
| EFFECT | Filing | Aug 19, 2021 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 19, 2021 | Aug 19, 2021 |
| CORRESP | Letter to the SEC | Aug 17, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2021 | — |
| S-3 | Shelf registration | Aug 10, 2021 | — |
| 8-K |
Current report
Results of operations
|
Aug 10, 2021 | Aug 10, 2021 |
| 10-Q | Quarterly report | Aug 10, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 28, 2021 | Jul 28, 2021 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 6, 2021 | Jul 6, 2021 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2021 | Jun 8, 2021 |
| 4 | Insider transaction | Jun 10, 2021 | Jun 8, 2021 |
| 4 | Insider transaction | Jun 10, 2021 | Jun 8, 2021 |
| 4 | Insider transaction | Jun 10, 2021 | Jun 8, 2021 |
| 4 | Insider transaction | Jun 10, 2021 | Jun 8, 2021 |
| 4 | Insider transaction | Jun 10, 2021 | Jun 8, 2021 |
| 4 | Insider transaction | May 20, 2021 | May 18, 2021 |
| 8-K |
Current report
Results of operations
|
May 12, 2021 | May 12, 2021 |
| 10-Q | Quarterly report | May 12, 2021 | Mar 31, 2021 |
| DEFR14A | Filing | May 5, 2021 | — |
| DEFA14A | Additional proxy material | Apr 23, 2021 | — |
| DEF 14A | Proxy statement | Apr 23, 2021 | Jun 8, 2021 |
| SC 13D/A | Amended ownership over 5% (active) | Mar 26, 2021 | — |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRKR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1094038
- Former names
- TAPIMMUNE INC. (until Oct 17, 2018); TAPIMMUNE INC (until Jun 29, 2017); GENEMAX CORP (until Jun 28, 2007); EDUVERSE COM (until Jun 17, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.